DE69226739T2 - Arzneimittel enthaltend Protein-gebundende Liposome - Google Patents

Arzneimittel enthaltend Protein-gebundende Liposome

Info

Publication number
DE69226739T2
DE69226739T2 DE69226739T DE69226739T DE69226739T2 DE 69226739 T2 DE69226739 T2 DE 69226739T2 DE 69226739 T DE69226739 T DE 69226739T DE 69226739 T DE69226739 T DE 69226739T DE 69226739 T2 DE69226739 T2 DE 69226739T2
Authority
DE
Germany
Prior art keywords
containing protein
medicament containing
bound liposomes
residues
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69226739T
Other languages
English (en)
Other versions
DE69226739D1 (de
Inventor
Toshiaki Tagawa
Saiko Hosokawa
Kazuhiro Nagaike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Application granted granted Critical
Publication of DE69226739D1 publication Critical patent/DE69226739D1/de
Publication of DE69226739T2 publication Critical patent/DE69226739T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
DE69226739T 1991-05-23 1992-05-20 Arzneimittel enthaltend Protein-gebundende Liposome Expired - Fee Related DE69226739T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11876291A JP3220180B2 (ja) 1991-05-23 1991-05-23 薬剤含有タンパク質結合リポソーム

Publications (2)

Publication Number Publication Date
DE69226739D1 DE69226739D1 (de) 1998-10-01
DE69226739T2 true DE69226739T2 (de) 1999-02-11

Family

ID=14744436

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69226739T Expired - Fee Related DE69226739T2 (de) 1991-05-23 1992-05-20 Arzneimittel enthaltend Protein-gebundende Liposome

Country Status (7)

Country Link
US (1) US5264221A (de)
EP (1) EP0526700B1 (de)
JP (1) JP3220180B2 (de)
AT (1) ATE170083T1 (de)
CA (1) CA2069244C (de)
DE (1) DE69226739T2 (de)
ES (1) ES2120972T3 (de)

Families Citing this family (321)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US6787153B1 (en) 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US5540935A (en) * 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US5463066A (en) * 1993-12-06 1995-10-31 Nof Corporation Phospholipid derivative and reactive vesicle-forming agent
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5658588A (en) * 1995-03-31 1997-08-19 University Of Cincinnati Fibrinogen-coated liposomes
GB9509016D0 (en) * 1995-05-03 1995-06-21 Royal Free Hosp School Med Tissue entrapment
US6673364B1 (en) * 1995-06-07 2004-01-06 The University Of British Columbia Liposome having an exchangeable component
CA2279673A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses
CA2202103C (en) 1996-04-11 2007-01-09 Toshiaki Tagawa Method for preparing closed vesicles
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
WO1998007409A1 (en) * 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
EP0932390A1 (de) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutische liposomenzusammensetzung und verfahren
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6224903B1 (en) 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6528271B1 (en) * 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
KR19990029749A (ko) * 1997-09-17 1999-04-26 미우라 아끼라 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US6083923A (en) * 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US20020114829A1 (en) * 1998-12-18 2002-08-22 Hayat Onyuksel Materials and methods for making improved liposome compositions
EP1170018A4 (de) * 1999-03-17 2002-04-17 Mitsubishi Chem Corp Ligandgebundener komplex
US20050074499A1 (en) * 1999-03-17 2005-04-07 Mitsubishi Chemical Corporation Ligand-bonded complex
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
EP1563832A1 (de) * 1999-04-23 2005-08-17 Mitsubishi Chemical Corporation Liposom enthaltend eine Verbindung mit 2 Polyalkylenglykol-Gruppen
GB9915074D0 (en) * 1999-06-28 1999-08-25 Cortecs Plc Ligand-binding composition
EP1235618A2 (de) * 1999-09-07 2002-09-04 Conjuchem, Inc. In vivo biokonjugierung an pulmonären oder blutkomponenten
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US7279324B2 (en) * 2001-01-23 2007-10-09 Duke University Nucleic acid encoding G-protein coupled receptor with modified DRY motif
JP5175020B2 (ja) * 2001-04-30 2013-04-03 サイティミューン サイエンシーズ， インコーポレイテッド コロイド状金属組成物および方法
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
MXPA03011985A (es) 2001-06-20 2004-03-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
CA2451643C (en) 2001-06-21 2012-11-13 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
WO2003009870A1 (fr) * 2001-07-25 2003-02-06 Mitsubishi Pharma Corporation Remedes traitant le cancer du sein
US20050032132A1 (en) * 2001-07-25 2005-02-10 Hisae Niki Cancer diagnostics
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
ES2390531T3 (es) 2001-09-18 2012-11-13 Genentech, Inc. Composiciones y procedimientos para el diagnósitco y tratamiento de tumor
NZ585001A (en) 2001-10-09 2011-08-26 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expression
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
AU2002368202B2 (en) 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
EP1452597A4 (de) * 2001-12-04 2006-09-20 Mitsubishi Pharma Corp Verfahren zur aktivierung von protein
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP2067472A1 (de) 2002-01-02 2009-06-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US20060193906A1 (en) * 2002-01-30 2006-08-31 National Institute Of Advanced Industrial Science And Technology Sugar-modified liposome and products comprising the liposome
US7070801B2 (en) * 2002-01-30 2006-07-04 National Institute Of Advanced Industrial Science And Technology Sugar-modified liposome and products comprising the liposome
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
JP2005538186A (ja) * 2002-09-13 2005-12-15 レプリコール インコーポレーティッド 非配列相補性の抗ウイルス性オリゴヌクレオチド
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
EP1549767A4 (de) 2002-09-26 2006-06-07 Amgen Inc Modulation der expression von forkhead-box o1a
US20060057147A1 (en) 2002-10-04 2006-03-16 Mitsubishi Pharma Corporation Antibody recognizing antibody
EP1560839A4 (de) 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc Chimäre oligomere verbindungen und derenverwendung in der genmodulation
EP1578765A4 (de) 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc Oligomere verbindungen,die zuckerersatzstoffe enthalten, und zusammensetzung zur verwendung in dergenmodulation
EP1569695B1 (de) 2002-11-13 2013-05-15 Genzyme Corporation Antisense-modulation von apolipoprotein-b-expression
DK2336318T3 (da) 2002-11-13 2013-07-15 Genzyme Corp Antisense-modulering af apolipoprotein b-ekspression
EP1568360A4 (de) * 2002-11-15 2011-06-29 Nipro Corp Liposom
US20050158375A1 (en) * 2002-11-15 2005-07-21 Toshikiro Kimura Pharmaceutical composition containing liposomes for treating cancer
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
AU2003289455A1 (en) * 2002-12-20 2004-07-14 Mitsubishi Pharma Corporation Method of protecting thiol group of protein
CA2515484C (en) 2003-02-11 2011-09-20 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
AU2004231740A1 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
WO2005002507A2 (en) 2003-06-03 2005-01-13 Isis Pharmaceuticals, Inc. Modulation of survivin expression
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP2182063A3 (de) 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulierung von EIF4E-Expression
US20050074453A1 (en) * 2003-10-02 2005-04-07 Ferree Bret A. Methods of preventing adhesions following laminectomies and other surgical procedures
EP1678194B1 (de) 2003-10-10 2013-06-26 Alchemia Oncology Pty Limited Modulation der synthese und des abbaus von hyaluronan bei der behandlung von krankheiten
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
JP4901478B2 (ja) 2003-11-17 2012-03-21 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
JP2008504216A (ja) 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
EP1711606A2 (de) 2004-01-20 2006-10-18 Isis Pharmaceuticals, Inc. Modulation der expression des glucocorticoidrezeptors
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US20050175584A1 (en) * 2004-01-28 2005-08-11 Paciotti Giulio F. Functionalized colloidal metal compositions and methods
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP1735009A4 (de) * 2004-03-12 2011-03-30 Alnylam Pharmaceuticals Inc Irna mittel targeting vegf
EP1579850A3 (de) * 2004-03-15 2009-12-16 Nipro Corporation Pharmazeutische Zubereitung mit Lipsomen zur Behandlung von Krebs
EP2700720A3 (de) 2004-03-15 2015-01-28 Isis Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
AU2005223654A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
CA2561221C (en) * 2004-03-26 2016-09-20 Curis, Inc. Rna interference modulators of hedgehog signaling and uses thereof
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
CN101001633A (zh) * 2004-05-21 2007-07-18 特兰萨夫公司 肺病和肺病前期病症的治疗
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US20090048192A1 (en) * 2004-06-03 2009-02-19 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
JP4692983B2 (ja) 2004-07-12 2011-06-01 独立行政法人科学技術振興機構 リポソーム封入物質がエンドソームから脱出可能なリポソーム
US7709539B2 (en) * 2004-08-11 2010-05-04 Chang Gung University Therapeutic use of resveratrol for hyperglycemia
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US9315862B2 (en) * 2004-10-05 2016-04-19 California Institute Of Technology Aptamer regulated nucleic acids and uses thereof
CA2584673A1 (en) * 2004-11-08 2006-05-26 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
EP1855694B1 (de) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense-zusammensetzung zur behandlung von muskelatrophie
WO2006088245A1 (ja) 2005-02-18 2006-08-24 The University Of Tokushima ポリオキシアルキレン鎖含有脂質誘導体及び該誘導体を含有する脂質膜構造体
CN101175769A (zh) 2005-03-10 2008-05-07 健泰科生物技术公司 用于调控血管完整性的方法和组合物
WO2006101201A1 (ja) 2005-03-24 2006-09-28 National University Corporation Hokkaido University 目的物質を効率的に核内に送達可能なリポソーム
PL1866414T3 (pl) 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
EP1877038B1 (de) * 2005-04-29 2017-03-22 University Of Louisville Research Foundation, Inc. Zelloberflächendekoration mit aktiven agentien
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP5043672B2 (ja) 2005-10-28 2012-10-10 田辺三菱製薬株式会社 新規細胞膜透過ペプチド
BRPI0618214A2 (pt) * 2005-11-01 2011-08-23 Alnylam Pharmaceuticals Inc inibição de rnai de replicação do influenza vìrus
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
JP2009516710A (ja) 2005-11-21 2009-04-23 アイシス ファーマシューティカルズ， インコーポレーテッド ｅＩＦ４Ｅ−ＢＰ２の発現のモジュレート
PT2161038E (pt) 2006-01-26 2014-03-10 Isis Pharmaceuticals Inc Composições e suas utilizações dirigidas à huntingtina
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
US20090082254A1 (en) * 2006-02-14 2009-03-26 Novo Nordisk A/S Coupling of Polypeptides at the C-Terminus
KR101547579B1 (ko) 2006-03-31 2015-08-27 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 유전자의 발현을 억제하는 이본쇄 리보핵산
WO2007126455A2 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
US7691824B2 (en) * 2006-04-28 2010-04-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the JC virus
CA2651031A1 (en) 2006-05-03 2007-11-08 Baltic Technology Development, Ltd. Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
CN101489566B (zh) * 2006-05-19 2012-04-18 阿尔尼拉姆医药品有限公司 Aha基因的RNAi调控及其治疗性应用
CA2653451C (en) 2006-05-22 2015-12-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US8048448B2 (en) * 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
JP2008031142A (ja) * 2006-06-29 2008-02-14 Hokkaido Univ 脂肪組織標的化ペプチド及び該ペプチドを有するリポソーム
US8198253B2 (en) 2006-07-19 2012-06-12 Isis Pharmaceuticals, Inc. Compositions and their uses directed to HBXIP
WO2008058291A2 (en) 2006-11-09 2008-05-15 California Institute Of Technology Modular aptamer-regulated ribozymes
JP5364381B2 (ja) * 2006-12-08 2013-12-11 片山化学工業株式会社 アンミン白金錯体を高濃度で内包するリポソームおよびその製造方法
US8048998B2 (en) * 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
WO2008094945A2 (en) 2007-01-29 2008-08-07 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
KR101508397B1 (ko) 2007-02-22 2015-04-08 제넨테크, 인크. 염증성 장 질환의 검출 방법
JP5350360B2 (ja) 2007-03-29 2013-11-27 アルナイラム ファーマシューティカルズ， インコーポレイテッド エボラ由来の遺伝子の発現を阻害するための組成物および方法
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
WO2009011855A2 (en) * 2007-07-16 2009-01-22 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US8865667B2 (en) * 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
KR20100123674A (ko) * 2007-09-21 2010-11-24 싸이티뮨 사이언스, 인크. 나노치료제 콜로이드성 금속 조성물 및 방법
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
CA2700953A1 (en) 2007-10-02 2009-04-09 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
JP5530933B2 (ja) 2007-12-10 2014-06-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド 第ｖｉｉ因子遺伝子発現阻害のための組成物及び方法
US20110118340A1 (en) * 2008-02-08 2011-05-19 Muthiah Manoharan Delivery of rnai constructs to oligodendrocytes
JP2011518117A (ja) * 2008-03-05 2011-06-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｅｇ５およびＶＥＧＦ遺伝子の発現を阻害するための組成物および方法
CA2720473A1 (en) 2008-04-04 2009-10-08 Calando Pharmaceuticals, Inc. Compositions and use of epas1 inhibitors
US20110076296A1 (en) 2008-04-25 2011-03-31 Innate Pharma S.A. TLR3 Agonist Compositions
WO2009148169A1 (ja) * 2008-06-06 2009-12-10 片山化学工業株式会社 アンミン白金錯体を高濃度に内包するリポソームを用いた腫瘍治療技術
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
EP3081648A1 (de) 2008-08-25 2016-10-19 Excaliard Pharmaceuticals, Inc. Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
WO2010028054A1 (en) 2008-09-02 2010-03-11 Alnylam Europe Ag. Compositions and methods for inhibiting expression of mutant egfr gene
JP2012502991A (ja) 2008-09-22 2012-02-02 アールエックスアイ ファーマシューティカルズ コーポレーション 皮膚適用におけるｒｎａ干渉
EP2334793B1 (de) 2008-09-25 2016-04-06 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
EA029762B1 (ru) 2008-10-20 2018-05-31 Элнилэм Фармасьютикалз, Инк. Композиции и способы для ингибирования экспрессии транстиретина
US20110230399A1 (en) * 2008-11-25 2011-09-22 Bowen Richard L Methods for Treating Obesity Related Disease
MX366774B (es) 2008-12-04 2019-07-24 Curna Inc Uso de oligonucleótidos antisentido en la inhibición de transcrito antisentido natural para sirtuina 1.
ES2637063T3 (es) 2008-12-04 2017-10-10 Curna, Inc. Tratamiento de enfermedades relacionadas con genes supresores de tumor mediante inhibición del transcrito antisentido natural al gen
WO2010065792A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
WO2010068816A1 (en) 2008-12-10 2010-06-17 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US20110319476A1 (en) 2009-02-12 2011-12-29 Opko Curna, Llc Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
PL2396038T3 (pl) 2009-02-12 2016-05-31 Curna Inc Leczenie chorób związanych z neurotropowym czynnikiem pochodzenia mózgowego (bdnf) poprzez zahamowanie naturalnego antysensownego transkryptu bdnf
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
EP2403946A4 (de) 2009-03-04 2012-11-14 Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
JP6032724B2 (ja) 2009-03-12 2016-11-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 脂質製剤組成物およびＥｇ５遺伝子とＶＥＧＦ遺伝子の発現を阻害する方法
US9464287B2 (en) 2009-03-16 2016-10-11 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
CA2755404C (en) 2009-03-17 2020-03-24 Joseph Collard Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
EP3248618A1 (de) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
US8318690B2 (en) 2009-05-01 2012-11-27 Curna, Inc. Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG
CN106237345A (zh) 2009-05-06 2016-12-21 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
ES2609655T3 (es) 2009-05-06 2017-04-21 Curna, Inc. Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
JP5922017B2 (ja) 2009-05-18 2016-05-24 クルナ・インコーポレーテッド リプログラミング因子に対する天然アンチセンス転写物の抑制によるリプログラミング因子関連疾患の治療
WO2010135695A2 (en) 2009-05-22 2010-11-25 Curna, Inc. TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
EP2435571B1 (de) 2009-05-28 2016-12-14 CuRNA, Inc. Behandlung von durch antivirale gene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein antivirales gen
KR101801404B1 (ko) 2009-06-16 2017-12-20 큐알엔에이, 인크. 콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
ES2629339T3 (es) 2009-06-16 2017-08-08 Curna, Inc. Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
KR101807324B1 (ko) 2009-06-26 2017-12-08 큐알엔에이, 인크. 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
CA2769665A1 (en) 2009-08-05 2011-02-10 Opko Curna, Llc Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
KR101892760B1 (ko) 2009-08-25 2018-08-28 큐알엔에이, 인크. ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
DK2473522T3 (en) 2009-09-02 2016-11-28 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
EP2488210A4 (de) 2009-10-12 2014-04-30 Smith Holdings Llc Verfahren und zusammensetzungen zur modulation der genexpression mit in-vivo oder in-vitro verabreichten arzneistoffen auf oligonukleotidbasis
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
US20120244169A1 (en) 2009-11-06 2012-09-27 Fibrogen, Inc. Treatment for Radiation-Induced Disorders
PE20121584A1 (es) 2009-11-30 2012-11-29 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
JP2013513588A (ja) 2009-12-11 2013-04-22 ジーンコード エーエス Ｇｄｎｆファミリーリガンド（ｇｆｌ）のミメティックまたはｒｅｔシグナル経路活性化因子を用いた、神経系細胞の生存を容易にするための方法
ES2661813T3 (es) 2009-12-16 2018-04-04 Curna, Inc. Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1
EP2515947B1 (de) 2009-12-23 2021-10-06 CuRNA, Inc. Behandlung von durch das uncoupling protein 2 (ucp2) bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts für ucp2
WO2011079261A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
RU2615450C2 (ru) 2009-12-29 2017-04-04 Курна, Инк. Лечение заболеваний, связанных с ядерным респираторным фактором 1(nrf1), путем ингибирования природного антисмыслового транскрипта к nrf1
JP5982288B2 (ja) 2009-12-29 2016-08-31 カッパーアールエヌエー，インコーポレイテッド 腫瘍タンパク質６３（ｐ６３）に対する天然アンチセンス転写物の阻害による腫瘍タンパク質６３関連疾患の治療
DK2521784T3 (en) 2010-01-04 2018-03-12 Curna Inc TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
JP5963680B2 (ja) 2010-01-06 2016-08-03 カッパーアールエヌエー，インコーポレイテッド 膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
WO2011085347A2 (en) 2010-01-11 2011-07-14 Opko Curna, Llc Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
WO2011090971A2 (en) 2010-01-19 2011-07-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
ES2671877T3 (es) 2010-01-25 2018-06-11 Curna, Inc. Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
CN102844435B (zh) 2010-02-22 2017-05-10 库尔纳公司 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
KR20130004579A (ko) 2010-02-23 2013-01-11 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2011235276B2 (en) 2010-03-29 2015-09-03 Alnylam Pharmaceuticals, Inc. SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
EP2556160A4 (de) 2010-04-09 2013-08-21 Curna Inc Behandlung von erkrankungen im zusammenhang mit dem fibroblastenwachstumsfaktor 21 (fgf21) mittels hemmung des natürlichen antisense-transkripts gegen fgf21
WO2011132713A1 (ja) 2010-04-21 2011-10-27 国立大学法人北海道大学 核内移行性を有する脂質膜構造体
ES2625689T3 (es) 2010-04-29 2017-07-20 Ionis Pharmaceuticals, Inc. Modulación de la expresión de transtiretina
CN107090045A (zh) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US9457079B2 (en) 2010-05-12 2016-10-04 The Trustees Of Columbia University In The City Of New York Methods for producing enteroendocrine cells that make and secrete insulin
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
KR20180053419A (ko) 2010-05-26 2018-05-21 큐알엔에이, 인크. 무조(無調)의 동소체 1 (atoh1)에 대한 자연 안티센스 전사체의 저해에 의한 atoh1 관련된 질환의 치료
EP2576579B1 (de) 2010-06-02 2018-08-08 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von leberfibrose
WO2012009402A2 (en) 2010-07-14 2012-01-19 Opko Curna Llc Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
AU2011312205B2 (en) 2010-10-05 2015-08-13 Curis, Inc. Mutant smoothened and methods of using the same
CA2813901C (en) 2010-10-06 2019-11-12 Curna, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
EP2630241B1 (de) 2010-10-22 2018-10-17 CuRNA, Inc. Behandlung von alpha-l-iduronidase (idua)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen idua
ES2677070T3 (es) 2010-10-27 2018-07-27 Curna, Inc. Tratamiento de enfermedades relacionadas con el regulador del desarrollo 1 asociado a interferón (ifrd1) mediante inhibición del transcrito antisentido natural al gen ifrd1
US20140134181A1 (en) 2010-11-05 2014-05-15 Kenneth E. Lipson Treatment Method For Lung Remodeling Diseases
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
US9279106B2 (en) 2010-11-12 2016-03-08 Georgetown University Immortalization of epithelial cells and methods of use
ES2657590T3 (es) 2010-11-23 2018-03-06 Curna, Inc. Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
EP2648763A4 (de) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
WO2012078967A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (epo) production
TWI593416B (zh) 2011-02-02 2017-08-01 艾克厘德製藥公司 利用針對結締組織生長因子（ｃｔｇｆ）目標之反義化合物治療瘢痕或肥厚性疤痕之方法
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
JP6108628B2 (ja) 2011-03-29 2017-04-05 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｔｍｐｒｓｓ６遺伝子の発現を阻害する組成物および方法
EP2694660B1 (de) 2011-04-03 2018-08-08 The General Hospital Corporation Effiziente in-vivo-proteinexpression mittels modifizierter rna (mod-rna)
CN105886506A (zh) 2011-04-13 2016-08-24 Isis制药公司 Ptp1b 表达的反义调节
SG10201805199RA (en) 2011-06-02 2018-07-30 Harvard College Methods and Uses for Ex Vivo Tissue Culture Systems
RU2620980C2 (ru) 2011-06-09 2017-05-30 Курна, Инк. Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2839437A1 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
EP3388068A1 (de) 2011-06-21 2018-10-17 Alnylam Pharmaceuticals, Inc. Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
CA2839896A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
RU2631805C2 (ru) 2011-06-21 2017-09-26 Элнилэм Фармасьютикалз, Инк. Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
EP3366312A1 (de) 2011-06-23 2018-08-29 Alnylam Pharmaceuticals, Inc. Serpina 1 sirnas: materialzusammensetzungen und verfahren zur behandlung
EP2724156B1 (de) 2011-06-27 2017-08-16 The Jackson Laboratory Verfahren und zusammensetzungen zur behandlung von krebs und autoimmunerkrankungen
US20140328811A1 (en) 2011-08-01 2014-11-06 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP3401401B1 (de) 2011-09-20 2020-04-15 Ionis Pharmaceuticals, Inc. Antisense-modulation der gcgr-expression
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
RU2014119787A (ru) 2011-10-25 2015-12-10 Айсис Фармасьютикалс, Инк. Антисмысловая регуляция экспрессии gccr
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
JP2015530387A (ja) 2012-09-04 2015-10-15 エライゾン ファーマシューティカルズ， エルエルシー 脂質複合体化シスプラチンによる肺癌の再発防止
EP2943194A1 (de) 2012-09-17 2015-11-18 Chemedest Ltd. Behandlung peripherer neuropathie mit gfr (alpha)-typ-3 -rezeptoragonisten
CN102920658B (zh) * 2012-11-02 2015-01-21 艾韦特(溧阳)医药科技有限公司 与glp-1类似物和聚乙二醇结合的脂质体及其制备方法
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2014152497A2 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
CA2918194C (en) 2013-03-27 2022-12-06 The General Hospital Corporation Methods and agents for treating alzheimer's disease
AR096203A1 (es) 2013-05-06 2015-12-16 Alnylam Pharmaceuticals Inc Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
US20160129089A1 (en) 2013-06-13 2016-05-12 Antisense Therapeutics Ltd Combination therapy
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
WO2015035231A1 (en) 2013-09-05 2015-03-12 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
EP3047023B1 (de) 2013-09-19 2019-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zusammensetzungen und methoden zur inhibierung des jc virus (jcv)
EP3052626A1 (de) 2013-10-02 2016-08-10 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
UA124961C2 (uk) 2013-10-04 2021-12-22 Елнілем Фармасьютикалз, Інк. ДВОНИТКОВА РИБОНУКЛЕЇНОВА КИСЛОТА (dsRNA) ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ALAS1
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3082760A1 (de) 2013-12-19 2016-10-26 Novartis AG Leptin-mrna-zusammensetzungen und -formulierungen
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015171918A2 (en) 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
US10487314B2 (en) 2014-06-26 2019-11-26 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016081728A1 (en) 2014-11-19 2016-05-26 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for frailty associated with aging
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
WO2016100716A1 (en) 2014-12-18 2016-06-23 Vasant Jadhav Reversirtm compounds
US11400139B2 (en) 2015-01-20 2022-08-02 The Children's Medical Center Corporation Anti-NET compounds for treating and preventing fibrosis and for facilitating wound healing
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
BR112018000054A2 (pt) 2015-07-02 2018-09-04 Otsuka Pharmaceutical Co., Ltd. composições farmacêuticas liofilizadas
AU2016295168B2 (en) 2015-07-17 2021-08-19 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
TW201718857A (zh) 2015-09-14 2017-06-01 艾爾妮蘭製藥公司 用於抑制alas1基因表現之組合物及方法
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
EP3858993A1 (de) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von duchenne-muskeldystrophie und damit assoziierten erkrankungen
ES2938883T3 (es) 2015-11-05 2023-04-17 Los Angeles Childrens Hospital Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
JP7040774B2 (ja) 2016-03-01 2022-03-23 マックォーリー・ユニバーシティ 神経学的症状の治療のためのリン酸化ｔａｕ及びｐ３８ガンマの使用
SG11201808964PA (en) 2016-04-18 2018-11-29 Sarepta Therapeutics Inc Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
WO2018209288A1 (en) 2017-05-12 2018-11-15 Massachusetts Institute Of Technology Argonaute protein-double stranded rna complexes and uses related thereto
CN110740985B (zh) 2017-06-15 2022-08-02 国立大学法人北海道大学 用于siRNA细胞内递送的脂质膜结构体
AU2018297262A1 (en) 2017-07-06 2020-02-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of alpha-ENaC and methods of use
SG11202000932XA (en) 2017-08-03 2020-02-27 Otsuka Pharma Co Ltd Drug compound and purification methods thereof
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
CA3096274A1 (en) 2018-04-06 2019-10-10 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
EP3788147A1 (de) 2018-05-04 2021-03-10 Tollys Tlr3-liganden, die sowohl epitheliale als auch myeloische zellen aktivieren
TW202020157A (zh) 2018-08-16 2020-06-01 美商艾爾妮蘭製藥公司 用於抑制lect2基因表現之組合物及方法
US20220024999A1 (en) 2018-11-29 2022-01-27 Flagship Pioneering Innovations V, Inc. Methods of modulating rna
US20220290152A1 (en) 2019-09-03 2022-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
US20220389429A1 (en) 2019-10-04 2022-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
EP4051796A1 (de) 2019-11-01 2022-09-07 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
IL295445A (en) 2020-02-10 2022-10-01 Alnylam Pharmaceuticals Inc Preparations and methods for silencing vegf-a expression
EP4127171A2 (de) 2020-03-30 2023-02-08 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
CA3179411A1 (en) 2020-04-06 2021-10-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing myoc expression
CN116134135A (zh) 2020-04-07 2023-05-16 阿尔尼拉姆医药品有限公司 用于沉默scn9a表达的组合物和方法
EP4153746A1 (de) 2020-05-21 2023-03-29 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
JP2024516168A (ja) 2021-04-22 2024-04-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド がんを治療するための組成物および方法
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
WO2024059165A1 (en) 2022-09-15 2024-03-21 Alnylam Pharmaceuticals, Inc. 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane

Also Published As

Publication number Publication date
CA2069244A1 (en) 1992-11-24
ATE170083T1 (de) 1998-09-15
US5264221A (en) 1993-11-23
DE69226739D1 (de) 1998-10-01
JPH04346918A (ja) 1992-12-02
CA2069244C (en) 2002-10-01
EP0526700B1 (de) 1998-08-26
ES2120972T3 (es) 1998-11-16
EP0526700A3 (de) 1994-01-26
JP3220180B2 (ja) 2001-10-22
EP0526700A2 (de) 1993-02-10

Similar Documents

Publication Publication Date Title
DE69226739D1 (de) Arzneimittel enthaltend Protein-gebundende Liposome
ATE104846T1 (de) Liposome.
MX9203480A (es) Formulaciones medicinales en aereosol.
DE68911473D1 (de) Arzneimittelformulierungen.
DE68912232D1 (de) Konjugate zytotoxischer Arzneimittel.
DE68927501T2 (de) Saugdüse
NO172097C (no) Utleveringsinnretning for drikkevarer
FI905510A0 (fi) Nya bensoxazinderivat och dessa innehaollande farmaceutiska blandningar.
FI930270A (fi) Cefalosporiner och homologer, framstaellningsfoerfaranden samt farmaceutiska kompositioner
DE3882157D1 (de) Nichtsteroide antientzuendungswirkstoffe enthaltende pharmazeutische zubereitungen.
FI900636A0 (fi) Permeationsoekande aemne innefattande etanol och glycerinmonooleat.
DE3791053T1 (de) Vakuum-molekularpumpe
DE69013557D1 (de) An Liposome gekuppelte bioaktive Verbindungen und ihre Verwendung in pharmazeutischen Zubereitungen.
FI893545A (fi) Maenskans protein c-mutanter och foerfarande foer deras framstaellning.
FI895268A0 (fi) Optiskt aktiva bensoxaziner och bensotiaziner och foerfarande foer deras stereospecifik framstaellning.
IT8819791A0 (it) Peptidi ad attivita' farmaceutica.
FI933165A (fi) Nya fosfolipidderivat
FI893366A0 (fi) 4-piperidylmetyl-2,3-dihydro-1h -isoindol- och 2,3,4,5-tetrahydro-1h-bensasepinderivat, deras framstaellning och terapeutiska anvaendning.
DE3891201T1 (de) Vakuum-molekularpumpe
FI912043A0 (fi) Pump foer automatisk och laongsam utstroemning fraon en laekemedelflaska.
IT8819790A0 (it) Peptidi ad attivita' farmaceutica.
ES1007934Y (es) Ventosa perfeccionada.
DE3770939D1 (de) Xylometazolinhaltige pharmazeutische praeparate.
ATE94382T1 (de) Adhaesives mittel zur arzneistoffabgabe.
FI885551A0 (fi) Skalningsmaskin och en daermed skalad produkt.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee